Decision on Norwegian PET (positron emission tomography) delayed
This article was originally published in Clinica
Executive Summary
Although the cost of introducing PET to Norway would be relatively high, its health benefits are obvious, says the leader of the Norwegian health and social committee, John Alvheim. He questioned why Norway's Scandinavian partners, Sweden and Denmark, had been using PET for some 20 years, but Norwegian cancer patients were not given access to the technology. "The number of people we could treat with this equipment would be several times the amount we currently do, using CT and MRI," said Mr Alvheim.
You may also be interested in...
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.